Abstract
Gallbladder cancer has a poor outcome because of its anatomy and location. Often, the diagnosis is made very late due to its silent course. Post-operated cases do respond to chemotherapy but the survival is counted in months and the quality of life is further hampered due to toxicity of drugs. Immunotherapy holds good promise in non-responding cancers treated by conventional chemotherapeutic agents. Among various therapies, dendritic cell therapy is growing at rapid pace due to its acceptable rationale. It has been utilized in treating successfully resected stage III (T2, N1, M0) gallbladder cancer in one of our patients. A 48 years old lady treated with this therapy is free of metastasis with ten doses of autologous dendritic cell vaccine constructed by utilizing resected tumor lysate antigen. She has received ten doses of therapy in 14 months of her treatment. This therapy has proven to be safe and without apparent side effects. The positive clinical response obtained supports that autologous dendritic cell-based immunotherapy is a promising therapeutic approach for refractory gallbladder cancers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albert, M.L., Darnell, J.C., Bender, A., Francisco, L.M., Bhardwaj, N., Darnell, R.B., 1998. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med., 4(11):1321–1324. [doi:10.1038/3315]
Banchereau, J., Schuler-Thurner, B., Palucka, A.K., Schuler, G., 2001. Dendritic cells as vectors for therapy. Cell, 106(3):271–274. [doi:10.1016/S0092-8674(01)00448-2]
Bartlett, D.L., Ramanathan, R.K., Deutsch, M., 2005. Cancer of the Biliary Tree. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (Eds.), Cancer, Principles and Practice of Oncology, 7th Ed. Lippincott Williams & Wilkins, USA, p.1023.
Batra, Y., Dutta, P.S., Dutta, U., Desai, P., Garg, P.K., Makharia, G., Ahuja, V., Pande, G.K., Sahni, P., Chattopadhyay, T.K., et al., 2005. Gallbladder cancer in India: a dismal picture. J. Gastroenterol. Hepatol., 20(2): 309–314. [doi:10.1111/j.1440-1746.2005.03576.x]
Dienstag, J.A., Isselbacher, K.J., 2001. Tumors of the Liver and Biliary Tract. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., Jameson, J.L. (Eds.), Harrison’s Principles of Internal Medicine, 15th International Ed. McGraw Hill, New Delhi, p.591.
Disis, M.L., Pupa, S.M., Gralow, J.R., Dittadi, R., Menard, S., Cheever, M.A., 1997. High titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol., 15:3363–3367.
Fleming, I.D., Cooper, J.S., Henson, D.E., Hutter, R.V.P., Kennedy, B.J., Murphy, G.P., Sullivan, B., Sobin, L.H., Yarbro, J.W., 1997. AJCC Cancer Staging Manual. Lippincott Williams & Wilkins, USA, p.103–105.
Ghadirian, P., Simard, A., Baillargeon, J., 1993. A population-based case-control study of cancer of the bile ducts and gall bladder in Quebec, Canada. Rev. Epidemiol. Sante Publique, 41:107.
Ikeda, K., Monden, T., Kanoh, T, Tsujie, M., Izawa, H., Haba, A., Ohnishi, T., Sekimoto, M., Tomita, N., Shiozaki, H., Monden, M., 1998. Extraction and analysis of diagnostically useful proteins from formalix-fixed, paraffin-embedded tissue sections. The Journal of Histochemistry and Cytochemistry, 46(3):397–403.
Khan, J.A., Yaqin, S., 2006. Dendritic cell therapy with improved outcome—a case report. J. Zhejiang Univ. SCIENCE B, 7(2):114–117. [doi:10.1631/jzus.2006.B0114]
Perpetuo, M.O., Valdivieso, M., Heilbrun, L.K., Nelson, R.S., Connor, T., Bodey, G.P., 1978. Natural history study of gall bladder cancer: a review of 36 years experience at M.D. Anderson hospital and tumor institute. Cancer, 42(1):330. [doi:10.1002/1097-0142(197807)42:1〈330::AID-CNCR2820420150〉3.0.CO;2-F]
Schlienger, K., Chu, C.S., Woo, E.Y., Rivers, P.M., Toll, A.J., Hudson, B., Maus, M.V., Riley, J.L., Choi, Y., Coukos, G., et al., 2003. TRANCE-and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin. Cancer Res., 9:1517–1527.
Slingluff, C.L., Engelhard, V.H., Ferrone, S., 2006. Peptide and dendritic cell vaccines. Clin. Cancer Res., 12(7):2342s–2345s. [doi:10.1158/1078-0432.CCR-05-2541]
Smythe, J.A., Fink, P.D., Logan, G.J., Lees, J., Rowe, P.B., Alexander, I.E., 1999. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. The Journal of Immunology, 163:3239–3249.
Srivastava, P.K., 2006. Therapeutic cancer vaccines. Curr. Opin. Immunol., 18(2):201–205. [doi:10.1016/j.coi.2006.01.009]
Steinman, R.M., Dhodapkar, M., 2001. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer, 94(4):459–473. [doi:10.1002/ijc.1503]
Author information
Authors and Affiliations
Additional information
Project partly supported by grant from Amim Cancer Trust and Patient’s Co-Operation, India
Rights and permissions
About this article
Cite this article
Khan, J.A., Yaqin, S. Successful immunological treatment of gallbladder cancer in India—Case report. J. Zhejiang Univ. - Sci. B 7, 719–724 (2006). https://doi.org/10.1631/jzus.2006.B0719
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1631/jzus.2006.B0719